Dr. Wei-Jia  Kong
My Social Links

Dr. Wei-Jia Kong

Research Professor
Chinese Academy of Medical Sciences, China


Highest Degree
Ph.D. in Virology from Chinese Academy of Medical Sciences, China

Share this Profile

Area of Interest:

Biomedical Sciences
100%
DNA Binding
62%
Transcription Factors
90%
Hydrobiology
75%
Bacterial Diseases
55%

Research Publications in Numbers

Books
0
Chapters
0
Articles
0
Abstracts
0

Selected Publications

  1. Zhang, Y., C. Wang, B. Yu, J.D. Jiang and W.J. Kong, 2018. Gastrodin protects against ethanol-induced liver injury and apoptosis in hepg2 cells and animal models of alcoholic liver disease. Biol. Pharm. Bull., 41: 670-679.
    Direct Link  |  
  2. Zhang, Y., W. Kong and J. Jiang, 2017. Prevention and treatment of cancer targeting chronic inflammation: Research progress, potential agents, clinical studies and mechanisms. Sci. China Life Sci., 60: 601-616.
    Direct Link  |  
  3. Ren, G., Y.X. Wang, Y.H. Li, D.Q. Song, W.J. Kong and J.D. Jiang, 2017. Structure-activity relationship of berberine derivatives for their glucose-lowering activities. Int. J. Clin. Exp. Med., 10: 5054-5060.
    Direct Link  |  
  4. Zheng Li, Zeng-Yan Zuo, Dan-Qing Song, Ying-Hong Li, Jian-Dong Jiang, Wei-Jia Kong 2016. Berberine Analogue Y53 has Improved Antioxidant and Anti-Inflammatory Activities in Diabetic C57BL/6J Mice with Liver Steatosis Int. J. Pharmacol., 12: 11-18.
    CrossRef  |  
  5. Wang, C., J.D. Jiang, W. Wu and W.J. Kong, 2016. The compound of mangiferin-berberine salt has potent activities in modulating lipid and glucose metabolisms in HepG2 cells. Bio Med. Res. Int., 10.1155/2016/8753436.
    CrossRef  |  Direct Link  |  
  6. Qu, L.L., B. Yu, Z. Li, W.X. Jiang, J.D. Jiang and W.J. Kong, 2016. Gastrodin ameliorates oxidative stress and proinflammatory response in nonalcoholic fatty liver disease through the AMPK/Nrf2 pathway. Phytother. Res., 30: 402-411.
    CrossRef  |  Direct Link  |  
  7. Yao, J., W.J. Kong and J.D. Jiang, 2015. Learning from berberine: Treating chronic diseases through multiple targets. Sci. China Life Sci., 58: 854-859.
    CrossRef  |  Direct Link  |  
  8. Qu, L., J. Jiang and W. Kong, 2014. Pharmacological effects of statins related to gap junction modulation. Pharmacol. Pharm., 5: 319-331.
    Direct Link  |  
  9. Li, Z., Y.N. Geng, J.D. Jiang and W.J. Kong, 2014. Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evidence-Based Complement. Alternat. Med. 10.1155/2014/289264.
    CrossRef  |  Direct Link  |  
  10. Li, Z., J.D. Jiang and W.J. Kong, 2014. Berberine up-regulates hepatic low-density lipoprotein receptor through ras-independent but AMP-activated protein kinase-dependent Raf-1 activation. Biol. Pharmaceut. Bull., 37: 1766-1775.
    CrossRef  |  Direct Link  |  
  11. Shan, Y.Q., Y.P. Zhu, J. Pang, Y.X. Wang, D.Q. Song, W.J. Kong and J.D. Jiang, 2013. Tetrandrine potentiates the hypoglycemic efficacy of berberine by inhibiting P-glycoprotein function. Biol. Pharm. Bull., 36: 1562-1569.
    CrossRef  |  Direct Link  |  
  12. Shan, Y.Q., G. Ren, Y.X. Wang, J. Pang and Z.Y. Zhao et al., 2013. Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux. Metabolism, 62: 446-456.
    CrossRef  |  Direct Link  |  
  13. Wang, Y.X., W.J. Kong, Y.H. Li, S. Tang and Z. Li et al., 2012. Synthesis and structure–activity relationship of berberine analogues in LDLR up-regulation and AMPK activation. Bioorg. Med. Chem., 20: 6552-6558.
    CrossRef  |  Direct Link  |  
  14. Li, Y., G. Ren, Y.X. Wang, W.J. Kong, P. Yang et al., 2011. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. J. Transl. Med., 10.1186/1479-5876-9-62.
    CrossRef  |  Direct Link  |  
  15. Zhang, H., W.J. Kong, Y.Q. Shan, D.Q. Song and Y. Li et al., 2010. Protein kinase D activation stimulates the transcription of the insulin receptor gene. Mol. Cell. Endocrinol., 330: 25-32.
    CrossRef  |  PubMed  |  Direct Link  |  
  16. Zhang, H., J. Wei, R. Xue, J.D. Wu and W. Zhao et al., 2010. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism, 59: 285-292.
    CrossRef  |  PubMed  |  
  17. Li, Y.H., Y. Li, P. Yang, W.J. Kong and X.F. You et al., 2010. Design, synthesis, and cholesterol-lowering efficacy for prodrugs of berberrubine. Bioorg. Med. Chem., 18: 6422-6428.
    CrossRef  |  
  18. Dai, W., W. He, G. Shang, J. Jiang, Y. Wang and W. Kong, 2010. Gene silencing of myofibrillogenesis regulator-1 by adenovirus-delivered small interfering RNA suppresses cardiac hypertrophy induced by angiotensin II in mice. AJP: Heart Circulatory Physiol., 299: H1468-H1475.
    CrossRef  |  
  19. Dai, W., J. Jiang, W. Kong and Y. Wang, 2010. Silencing MR-1 attenuates inflammatory damage in mice heart induced by angII. Biochem. Biophy. Res. Commun., 391: 1573-1578.
    CrossRef  |  Direct Link  |  
  20. Wang, Y.X., Y.P. Wang, H. Zhang, W.J. Kong and Y.H. Li et al., 2009. Synthesis and biological evaluation of berberine analogues as novel up-regulators for both low-density-lipoprotein receptor and insulin receptor. Bioorg. Med. Chem. Lett., 19: 6004-6008.
    CrossRef  |  PubMed  |  
  21. Li, Y.H., P. Yang, W.J. Kong, Y.X. Wang and C.Q. Hu et al., 2009. Berberine analogues as a novel class of the low-density-lipoprotein receptor up-regulators: synthesis, structure-activity relationships and cholesterol-lowering efficacy. J. Med. Chem., 52: 492-501.
    CrossRef  |  PubMed  |  Direct Link  |  
  22. Kong, W.J., H. Zhang, D.Q. Song, R. Xue and W. Zhao et al., 2009. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism, 58: 109-119.
    CrossRef  |  PubMed  |  Direct Link  |  
  23. Zhao, W., R. Xue, Z.X. Zhou, W.J. Kong and J.D. Jiang, 2008. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed. Pharm., 62: 730-731.
  24. Yang, P., D.Q. Song, Y.H. Li, W.J. Kong and Y.X. Wang et al., 2008. Synthesis and structure–activity relationships of berberine analogues as a novel class of low-density-lipoprotein receptor up-regulators. Bioorg. Med. Chem. Lett., 18: 4675-4677.
    CrossRef  |  Direct Link  |  
  25. Kong, W.J., J. Wei, Z.Y. Zuo, Y.M. Wang and D.Q. Song et al., 2008. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metab.-Clin. Exp., 57: 1029-1037.
    CrossRef  |  PubMed  |  Direct Link  |  
  26. Kong, W. J., J. Liu and J.D. Jiang, 2006. Human low-density lipoprotein receptor gene and its regulation. J. Mol. Med., 84: 29-36.
    Direct Link  |  
  27. Kong, W., P. Abidi, F.B. Kraemer, J.D. Jiang and J. Liu, 2005. In vivo activities of cytokine oncostatin M in the regulation of plasma lipid levels. J. Lipid Res., 46: 1163-1171.
    Direct Link  |  
  28. Kong, W., J. Wei, P. Abidi, M. Lin and S. Inaba et al., 2004. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med., 10: 1344-1351.
    CrossRef  |  Direct Link  |  
  29. Kong, W.J. and J.D. Jiang, 2003. Advances in anti-tumor therapy targeting the EGFR family of receptor tyrosine kinases. Chin. Pharmacol. Bull., 19: 847-850.
    Direct Link  |